Tumor-specific antigens.

M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old

doi:10.1007/978-3-642-81491-4_1

Home/Archive/PubMed

PubMed · 7232821

Tumor-specific antigens.

M Pfreundschuh·H Shiku·T Takahashi·R Ueda·J Ransohoff·H F Oettgen·L J Old

View original source ↗Export metadata ↓

Abstract

Based on autologous serological typing of cultured astrocytoma cells from 30 patients, three classes of surface antigens have been defined. Class I antigens are restricted to autologous astrocytoma cells. Class II antigens are shared by autologous as well as certain allogeneic tumors, but are not detected on normal cells. Class III antigens are not tumor-specific and are found on both normal and malignant cells. This analysis of human astrocytoma, with the recognition of three classes of surface antigens recognized by autologous sera, resembles the results of autologous typing of human malignant melanoma, acute leukemia, and renal carcinoma.

Explore related subjects

Antigens, Neoplasm Antigens, Surface Astrocytoma Fibroblasts Hemadsorption Humans Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M Pfreundschuh, H Shiku, T Takahashi, R Ueda, J Ransohoff, H F Oettgen, L J Old. 1980. Tumor-specific antigens.. https://doi.org/10.1007/978-3-642-81491-4_1

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

A proteomic study of SUMO-2 target proteins.

The SUMO family in vertebrates includes at least three distinct proteins (SUMO-1, -2, and -3) that are added as post-translational modifications to target proteins. A considerable number of SUMO-1 target proteins have been identified, but little is known about SUMO-2. A stable HeLa cell line expressing His6-tagged SUMO-2 was established and used to label and purify novel endogenous SUMO-2 target proteins. Tagged forms of SUMO-2 were functional and localized predominantly in the nucleus. His6-tagged SUMO-2 conjugates were affinity-purified from nuclear fractions and identified by mass spectrometry. Eight novel potential SUMO-2 target proteins were identified by at least two peptides. Three of these proteins, SART1, heterogeneous nuclear ribonucleoprotein (RNP) M, and the U5 small nuclear RNP 200-kDa helicase, play a role in RNA metabolism. SART1 and heterogeneous nuclear RNP M were both shown to be genuine SUMO targets, confirming the validity of the approach.

Antigens, Neoplasm↗

PubMed2002

Alterations of thyroid hormone receptor alpha gene: frequency and association with Nm23 protein expression and metastasis in gastric cancer.

Thyroid hormone receptor genes (c-erbA, or TR) have been implicated as tumor suppressor genes. We investigated whether two subtypes of TR genes (TRalpha and TRbeta) are altered in human gastric cancer, as well as the role of such alterations in tumor metastasis. As a preliminary survey (n=18), Southern blot analysis was conducted with full-length TRalpha or TRbeta cDNA probes, after digestion with restriction enzyme (EcoRI, BamHI, or HindIII). The survey showed the most frequent alteration was in TRalpha gene by a loss of two HindIII fragments (7.1 and 10.1 kb). Subsequent study focused at this TRalpha alteration by increasing patient number up to a total of 42. TRalpha alteration was noted in 19 (49%) of the 39 patients with informative results. The TRalpha alteration was associated with the development of distant (hematogenous) metastasis (P=0.0084) and high expression level of Nm23 protein (P=0.020). These findings suggest that TRalpha might be involved in tumorigenesis, and that interactions between the TRalpha and nm23 genes might take part in hematogenous metastasis of gastric cancer.

Antigens, Neoplasm↗

PubMed2002

Expression of cytokeratin 19 in human hepatocellular carcinoma cell lines.

It has been reported that the cytokeratin 19 (CK19) fragment, CYFRA 21-1, is increased in sera of some hepatocellular carcinoma patients. We hypothesized that CYFRA 21-1 might be released directly from hepatocellular carcinoma. To investigate this mechanism, we evaluated expression of CK19 in 8 human cell lines by immunoradiometric assay, Western blotting, immunohistochemistry, and reverse transcriptase-polymerase chain reaction in Chang liver cells, 2 cholangiocarcinoma cell lines, and 5 hepatocellular carcinoma cell lines. Three of 5 hepatocellular carcinoma cell lines released CYFRA 21-1, synthesized CK19 protein and expressed mRNA for CK19, as observed in 2 cholangiocarcinoma cell lines. In contrast, there was no expression of CK19 in Chang liver cells or 2 of 5 hepatocellular carcinoma cell lines. Analysis of genomic DNA for CK19 demonstrated that exon 1 was not amplified in the 3 cell lines not expressing CK19. However, there were no point mutations within exon 1 and the promoter region of CK19 in hepatocellular carcinoma cell lines. Our present study demonstrates that: i) the expression of CK19 was evident in some human hepatocellular carcinoma cell lines, and ii) the expression of mRNA for CK19 was related to the release of CYFRA 21-1. These results partially clarify the mechanism by which some hepatocellular carcinoma cell lines produce CK19 and others do not.

Antigens, Neoplasm↗